A new breakthrough in stress therapy! Nature sub-magazine points out that stress therapy is effective in treating ovarian cancer!

May 27, 2020 /
BiovalleyBIOON/-- High-level Plasma Ovarian Cancer (HGSOC) is the most common ovarian cancer, accounting for 70-80% of ovarian cancer deathsAlthough some new treatments have been approved for treatment for ovarian cancer, overall survival rates have not improved over the past few decadesin a new study published in the journal Nature Communications,researchers from the Peter Mac Cancer Center reported that HGSOC cells are sensitive to a new class of treatments that causetumors to stop growingcells, in some cases, and slow the growth of ovarian cancer in micethis new approach also applies to cancers that are resistant to current drugs, offering hope for a possible improvement in prognosis for patients with HGSOC who are resistant to current chemotherapy standardsPicture source: Nephron WikipediaCC BY-SA 3.0new treatment was developed based on the discovery that cancer cells are cell factories that indulge in the manufacture of ribosomes -- proteins that cells need to grow and surviveblocking a key part of the ribosome-generating pathway causes pressure levels within cancer cells to soar, causing DNA replication to stall and lead to stagnant growth and death of cancer cellsProfessor Rick Pearson, of peter Mac,the study, said: "Our early research shows that cancer cells are very dependent on the ability to make ribosomes, which can be used to selectively kill them"
" is a ground-breaking discovery that has identified a new way to treat cancer and led to the development of a new class of anticancer drugs for ribosomes "
this new ribosome-targeted drug, known as CX-5461, is currently in the stage of early clinical trials to treat some blood cancers, with promising results, and the researchers hope to extend it to the treatment of solid cancers, including HGSOC "We are particularly interested in whether CX-5461 is effective for ovarian cancer because we predict that it is most effective for cancers with defective DNA repair capabilities, including many gynecological cancers," said Dr Elaine Sanij of Peter Mac, co-leader of the study in collaboration with Professor Clare Scott of the Walter and Eliza hall institute, Peter Mac's team treated human ovarian cancer, which grows into tumors in mice, using CX-5461 and found that they could significantly slow the growth of tumor if it is The FDA approved the combination of PARP inhibitors (PARPi) for ovarian cancer treatment, which can significantly reduce tumors, leading to long-lasting tumors
subsides and prolongs survival important, CX-5461 is effective even in the "incurable" HGSOC, which has previously become resistant to conventional chemotherapy and PARPi "We are very excited to find that this new treatment has shown efficacy in some ovarian cancers, and no other treatment will respond," dr Sanij said next step will be to test whether CX-5461 is effective for women with HGSOC, especially in patients with drug-resistant diseases Professor Pearson, , said: "We believe this approach has great promise, and we are particularly encouraging the early clinical trials of CX-5461 in patients with drug-resistant blood cancer Trials have shown that the treatment has good tolerance and show
activity against tumors (biovalleybioon.com) Reference: New to stress out cancer cells is in in ovarian cancer
Elaine Sanij et al.
CX-5461 actives the DNA damage sylweding and the des efficofinacy in high-grade serous serous cancer , Nature Communications (2020) DOI: 10.1038/s41467-020-16393-4